Hubert Kettenberger
Overview
Explore the profile of Hubert Kettenberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bauer N, Boettger M, Papadaki S, Leitner T, Klostermann S, Kettenberger H, et al.
Front Bioeng Biotechnol
. 2024 Nov;
12:1414408.
PMID: 39530057
We present a detailed mass spectrometric analysis of three 2 + 1 T-cell bispecific monoclonal antibodies (TCB mAbs), where an unexpected +15.9950 Da mass shift in tryptic peptides was observed....
2.
Siegel M, Bolender A, Ducret A, Fraidling J, Hartman K, Looney C, et al.
Front Immunol
. 2024 Sep;
15:1406643.
PMID: 39263220
Introduction: Immunogenicity, the unwanted immune response triggered by therapeutic antibodies, poses significant challenges in biotherapeutic development. This response can lead to the production of anti-drug antibodies, potentially compromising the efficacy...
3.
Hoerschinger V, Waibl F, Pomarici N, Loeffler J, Deane C, Georges G, et al.
J Chem Inf Model
. 2023 Nov;
63(22):6964-6971.
PMID: 37934909
The electrostatic properties of proteins arise from the number and distribution of polar and charged residues. Electrostatic interactions in proteins play a critical role in numerous processes such as molecular...
4.
Fernandez-Quintero M, Ljungars A, Waibl F, Greiff V, Andersen J, Gjolberg T, et al.
MAbs
. 2023 Feb;
15(1):2171248.
PMID: 36823021
Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and...
5.
Waibl F, Fernandez-Quintero M, Wedl F, Kettenberger H, Georges G, Liedl K
Front Mol Biosci
. 2022 Sep;
9:960194.
PMID: 36120542
While antibody-based therapeutics have grown to be one of the major classes of novel medicines, some antibody development candidates face significant challenges regarding expression levels, solubility, as well as stability...
6.
Fernandez-Quintero M, Quoika P, Wedl F, Seidler C, Kroell K, Loeffler J, et al.
Front Mol Biosci
. 2022 Mar;
9:864654.
PMID: 35242816
[This corrects the article DOI: 10.3389/fmolb.2022.812750.].
7.
Fernandez-Quintero M, Quoika P, Wedl F, Seidler C, Kroell K, Loeffler J, et al.
Front Mol Biosci
. 2022 Feb;
9:812750.
PMID: 35155578
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies and other new formats, represent a key component in advancing antibody therapy....
8.
Liu S, Verma A, Kettenberger H, Richter W, Shah D
MAbs
. 2021 Oct;
13(1):1993769.
PMID: 34711143
A growing body of evidence supports the important role of molecular charge on antibody pharmacokinetics (PK), yet a quantitative description of the effect of charge on systemic and tissue disposition...
9.
Fernandez-Quintero M, Kroell K, Bacher L, Loeffler J, Quoika P, Georges G, et al.
Front Immunol
. 2021 Aug;
12:675655.
PMID: 34447370
Antibodies have emerged as one of the fastest growing classes of biotherapeutic proteins. To improve the rational design of antibodies, we investigate the conformational diversity of 16 different germline combinations,...
10.
Jakubiak P, Alvarez-Sanchez R, Fueth M, Broders O, Kettenberger H, Stubenrauch K, et al.
Mol Pharm
. 2021 May;
18(6):2208-2217.
PMID: 34014104
The current standard of care for antivascular endothelial growth factor (VEGF) treatment requires frequent intravitreal (IVT) injections of protein therapeutics, as a result of limited retention within the eye. A...